Pfizer says lung cancer drug fails two late-stage studies
Jan 27 (Reuters) - Pfizer Inc said its experimental lung cancer drug failed to meet its goals in two late-stage studies in patients with advanced non-small cell lung cancer.
The company said the drug, dacomitinib, did not show improved survival without the cancer worsening in patients when compared with another non-small cell lung cancer drug. The patients were previously treated with chemotherapy.
Pfizer said the drug did not prolong overall survival compared with a placebo in a second study.